Background {#Sec1}
==========

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare type of primary hepatic malignancy with high invasive features, and its incidence is second to that of hepatocellular carcinoma (HCC) \[[@CR1]\]. However, the morbidity and mortality of ICC have been increasing globally during the past decades. As a result of late diagnosis, ICC frequently presents with large and/or multiple tumors \[[@CR2], [@CR3]\]. Currently, the major treatment modalities consist of surgical resection, regional therapy, chemotherapy, and liver transplantation \[[@CR4]\], but the long-term prognosis of ICC remains disappointing because of the high recurrence rate \[[@CR5]\].

Several risk factors have been reported to be associated with the occurrence and development of ICC, and they include hepatolithiasis, hepatitis B and C virus infection, liver cirrhosis, and primary sclerosing cholangitis \[[@CR6], [@CR7]\]. Fibrosis (Fb), a liver tissue scar reaction involved in various types of chronic liver damage, is a complicated process with multiple steps ranging from chronic liver disease to cirrhosis \[[@CR8]\]. In fact, more than 80% of HCC cases are known to have developed in the setting of fibrosis or cirrhosis, with chronic inflammation, tissue regeneration, and other molecular events resulting in the production of reactive oxygen species, chromosomal mutations, and, eventually, the malignant transformation of proliferating hepatocytes \[[@CR9]\].

A limited number of studies have explored the relationships between liver fibrosis and the clinicopathological characteristics of ICC. Recent evidence suggests that cancer-associated fibroblasts (CAFs) and fibrosis in the tumor microenvironment promote the development and progression of cholangiocarcinoma (CCA) through multiple mechanisms involving multicellular signaling networks \[[@CR10]\]. Therefore, in the current study, we aim to investigate the impact of fibrosis on the overall survival (OS, measured from the date of diagnosis to the date of death) and disease-specific survival (DSS, defined as the interval from the date of diagnosis to the date of cancer-specific death \[[@CR11]\]) of ICC patients from the Surveillance, Epidemiology, and End Results (SEER) database (<http://www.seer.cancer.gov>) of the National Cancer Institute. This program has been published routinely and has archived 21 population-based cancer registries. It has also been deemed applicable to cancer-based epidemiology and survival analyses because of its comprehensive information coverage, which includes demographics, primary tumor site, tumor morphology, stage at diagnosis, main therapeutic course, follow-up records, etc.

Methods {#Sec2}
=======

Data source and study population {#Sec3}
--------------------------------

The database used in our study was the incidence--SEER 18 Regs Custom data (with additional treatment fields), Nov2018 Sub (1975--2016 varying). A total of 729 ICC patients were identified at clinical stages I--IV from a population of 141,625 candidates diagnosed with primary liver cancer between 2004 and 2015. Of the identified patients, 63.8% of them (n = 465) were assigned to the low fibrosis score (low-Fb score) group (Fb score of 0--4), and the remaining ones (n = 264, 36.2%) were assigned to the high fibrosis score (high-Fb score) group (Fb score of 5--6). The flowchart of this study is presented in Fig. [1](#Fig1){ref-type="fig"}, and details are provided in Supplementary file [1](#MOESM1){ref-type="media"}. Fig. 1Flowchart displaying the selection procedure of ICC cases in the SEER database

Parameters {#Sec4}
----------

Variables from the patient, tumor, and treatment levels were adopted in the statistical analysis. The patient-level parameters included age at diagnosis, sex, race, and marital status. The tumor-level variables included tumor number, tumor size, year of diagnosis (2004--2009 vs. 2010--2015), alpha-fetoprotein (AFP, cutoff value of 15 ng/mL), lymph node status, metastasis of diagnosis, tumor pathological grade, tumor node metastasis (TNM) stage, and Ishak Fb score. The treatment-level variables mainly included the surgery, radiation, and chemotherapy records of ICC patients. A full description of the variables is available in the SEER Data Management System User Manual (<https://seer.cancer.gov/tools/codingmanuals/index.html>) and CS Coding Instructions v0205.

Statistical analysis {#Sec5}
--------------------

Continuous variables were demonstrated as means with standard deviations (SD) and were compared using the student's t-test or Mann--Whitney U test. Categorical variables, presented as frequencies and percentages (%), were compared using the chi-square test or Fisher's exact test.

To balance the differences between the two groups, we constructed a propensity score model by using the variables of the entire logistic regression model for patients with high-Fb scores. The candidate variables included all variables significantly associated with high-Fb scores, as determined via a univariate analysis with a threshold of *P* \< 0.2. Then, propensity score matching (PSM) and inverse probability of weighting (IPW) methods were adopted to reduce the standard mean differences (SMDs) of the covariates. In PSM, individuals with low-Fb scores were matched to those with high-Fb scores by using a matching ratio of approximately 1:1, with the closest estimated propensity score values limited within 0.1 of the SD in the study population \[[@CR12]\]. All patients with high- and low-Fb scores were weighted by the propensity score model via the IPW method \[[@CR13], [@CR14]\]. Two matched cohorts (PSM cohort and IPW cohort) were generated to validate the associations of the Fb scores with the clinical outcomes of ICC patients. The Kaplan--Meier (KM) curves for the OS and compete risk survival analysis were derived to visualize the comparison between the high- and low-Fb scores. Cox regression analysis was performed to explore the risk factors influencing patient survival. Additionally, the treatment benefits for the ICC patients with high- and low-Fb scores were further explored and confirmed in the matched cohorts via stratified analyses based on treatment modalities. All the statistical analyses were performed in R (R Foundation for Statistical Computing, Vienna, Austria, Version 3.6.0), and the R packages of "forestplot," "glm," "ggolot2," "matching," "survey," and "cmprsk" were used. Two-tailed P \< 0.05 was considered to indicate statistical significance.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

According to the inclusion and exclusion criteria, 729 eligible ICC patients from the SEER database (2004--2015) were analyzed (Fig. [1](#Fig1){ref-type="fig"}). The baseline clinicopathological characteristics of the ICC patients in the high- and low-Fb score groups are listed in Table [1](#Tab1){ref-type="table"}. As shown in Fig. [2](#Fig2){ref-type="fig"}, despite the rising incidence, the proportion of patients with high-Fb scores did not significantly change over time. Table 1Demographic and clinical characteristics of ICC patients with different fibrosis scoreVariablesLow-fibrosis score groupHigh-fibrosis score group*P*\
*Value*No. of patient, n (%)465 (63.9)264 (36.1)Marital status, n (%)0.188 Married287 (61.7)146 (55.3) Single157 (33.8)107 (40.5) Unknown21 (4.5)11 (4.2)Age (mean (sd))65.94 (11.5)64.21 (9.9)0.040Age, ≤60, years, n (%)143 (30.8)92 (34.8)0.292Sex, male, n (%)218 (46.9)174 (65.9)\< 0.001Year of diagnosis, 2010--2015, n (%)321 (69.0)193 (73.1)0.282Ethnicity, n (%)0.053 Black31 (6.7)21 (8.0) White350 (75.3)213 (80.7) Other84 (18.1)30 (11.4)AFP, ng/ml, n (%)\< 0.001  ≤ 15219 (47.1)113 (42.8)  \> 1563 (13.5)79 (29.9) Unknown183 (39.4)72 (27.3)Number of tumors, single, n (%)338 (72.7)208 (78.8)0.082Tumor size, cm, n (%)0.013  \> 3323 (69.5)160 (60.6)  ≤ 363 (13.5)57 (21.6) Unknown79 (17.0)47 (17.8)Lymph nodes metastasis, n (%)0.499 No341 (73.3)190 (72.0) Yes112 (24.1)63 (23.9) Unknown12 (2.6)11 (4.2)Distance metastasis, n (%)0.013 No361 (77.6)181 (68.6) Yes98 (21.1)81 (30.7) Unknown6 (1.3)2 (0.8)6th AJCC TNM stage, n (%)0.008 I135 (29.0)84 (31.8) II54 (11.6)24 (9.1) III144 (31.0)55 (20.8) IV102 (21.9)83 (31.4) Unstaged30 (6.5)18 (6.8)Pathological grade, n (%)0.009 Grade I35 (7.5)12 (4.5) Grade II166 (35.7)74 (28.0) Grade III106 (22.8)57 (21.6) Grade IV5 (1.1)1 (0.4) Unstaged153 (32.9)120 (45.5)Surgery record, yes, n (%)241 (51.8)97 (36.7)\< 0.001Radiation record, yes, n (%)74 (15.9)35 (13.3)0.391Chemotherapy record, yes, n (%)215 (46.2)109 (41.3)0.224**Outcomes** Survival month (mean (sd))22.43 (24.74)16.67 (21.95)0.002 Vital status, dead, n (%)342 (73.5)212 (80.3)0.050 Compete risk, n (%)0.103  Alive123 (26.5)52 (19.7)  Dead with other reasons23 (4.9)17 (6.4)  Dead with cancer319 (68.6)195 (73.9)Abbreviation: *AFP* serum alpha fetoprotein, *AJCC* American Joint Committee on cancerFig. 2Number of patients with low-Fb scores versus high-Fb scores over time in the National Cancer Center Database, 2004--2015

Overall survival analysis and competing risk survival analysis before matching {#Sec8}
------------------------------------------------------------------------------

The median survival times in the low- and high-Fb score groups were 22.43 and 16.67 months, respectively. The OS analysis (Fig. [3](#Fig3){ref-type="fig"}a) showed that a high-Fb score was a significant risk factor of OS in ICC patients (HR 95%CI = 1.371 \[1.154--1.628\], *P* \< 0.001). Before matching, the one-, three-, and five-year OS rates were 50.9, 28.0, and 16.1% in the low-Fb score group and 39.3, 20.1, and 8.0% in the high-Fb score group (*P* \< 0.001), respectively. Table [2](#Tab2){ref-type="table"} shows the results of the univariate and multivariate Cox regression analyses in the unmatched cohort. We found that a high-Fb score was an independent risk factor of OS in ICC patients (HR 95%CI = 1.282 \[1.067--1.541\], *P* = 0.008). In addition to the Fb score, we identified being male, presence of multiple tumors, tumor size \> 3 cm, presence of distance metastasis, and advanced stage as risk factors of OS. Meanwhile, surgery treatment and chemotherapy were identified as protective factors of OS in ICC patients. In the competing risk survival analysis, the unadjusted P values of the Fb score for the death circumstance of ICC and other reasons were 0.005 and 0.369 in the primary cohort (Fig. [4](#Fig4){ref-type="fig"}a). Fig. 3Overall survival rates in (**a**) the unmatched, (**b**) the propensity score-matched, and (**c**) the inverse probability of treatment weight-adjusted analysis of ICC patientsTable 2The univariate and multivariate Cox analysis of overall survival in the unmatched cohortUnivariate analysisMultivariate analysisCharacteristicsHR95%CI*P value*HR95%CI*P value*Sex, Male vs. Female1.2391.047--1.4660.0131.3861.157--1.661\< 0.001Age years, ≤60 vs. \> 600.8380.701--1.0030.054Marital status Marriedref Single1.2111.017--1.4410.032 Unknown1.1750.788--1.7520.430Year of diagnosis, 2010--2015 vs. Elarly0.8380.702--1.0010.052Ethnicity Blackref Other0.7600.52--1.1120.157 White0.9170.66--1.2730.605 AFP, ng/mlref  \> 15 vs. ≤151.1400.906--1.4340.263 Unknown vs. ≤151.1340.925--1.3910.225 Fibrosis score, 5--6 vs. 0--41.3711.154--1.628\< 0.0011.2821.067--1.5410.008 Number of tumors, Multi vs. Single1.3851.138--1.6850.0011.5481.258--1.904\< 0.001Tumor size, cm 3 cmref  ≤ 3 cm0.4750.364--0.62\< 0.0010.5170.39--0.684\< 0.001 Unknown2.0291.647--2.499\< 0.001 Lymph nodes metastasis, Noref Yes1.7381.434--2.107\< 0.001 Unknown2.2401.427--3.516\< 0.001 Distance metastasis, Noref Yes3.6052.976--4.368\< 0.0012.3761.112--5.0780.026 Unknown5.0102.48--10.118\< 0.0012.7921.035--7.5330.043 6th AJCC TNM stage  Iref  II1.4711.065--2.0320.0191.9341.39--2.692\< 0.001  III2.2911.806--2.907\< 0.0012.4951.776--3.506\< 0.001  IV5.4024.245--6.875\< 0.0011.7500.695--4.4030.235  Unstaged3.9742.811--5.618\< 0.0014.1442.481--6.92\< 0.001Pathological grade Iref II0.9400.64--1.380.7510.6690.452--0.9910.045 III1.5451.043--2.2880.0300.9880.659--1.4810.954 IV1.2060.424--3.40.7310.7180.247--2.0820.542 Unstaged2.0261.391--2.951\< 0.0011.2350.831--1.8340.297Surgery record, Yes vs. No0.2210.184--0.266\< 0.0010.3050.242--0.383\< 0.001Radiation record, Yes vs. No0.8740.692--1.1020.255Chemotherapy record, Yes vs. No0.8300.702--0.9830.0310.4900.407--0.589\< 0.001Abbreviation: *HR* Hazard ratio, *CI* confidence interval, *AFP* serum alpha fetoprotein, *AJCC* American Joint Committee on cancerFig. 4Disease-specific survival in (**a**) the unmatched and (**b**) the propensity score-matched analysis of ICC patients

Factors associated with high-Fb scores in ICC patients {#Sec9}
------------------------------------------------------

A propensity score model was constructed on the basis of the multivariate logistic regression analysis (Table [3](#Tab3){ref-type="table"}). Compared with the patients in the low-Fb score group, those in the high-Fb score group were mostly single and male and were more likely to have higher AFP levels, small tumor size (≤3 cm), and multiple tumors. The 6th AJCC stage III was more inclined to occur in patients with high-Fb scores than in their counterparts. Table 3Propensity modeling of high fibrosis score (severe/cirrhosis) patientsVariablesOR95%CI*P value*Age, years  \> 60Reference  ≤ 600.9990.929--1.0740.987Sex FemaleReference Male1.1771.099--1.261**\< 0.001**Marital status MarriedReference Single1.0821.007--1.164**0.032** Unknown1.0570.894--1.2480.523Ethnicity BlackReference White0.9780.854--1.1200.749 Other0.8870.760--1.0350.129AFP, ng/ml  ≤ 15Reference  \> 151.2171.109--1.334**\< 0.001** Unknown0.9590.888--1.0350.286Tumor size, cm  \> 3 cmReference  ≤ 3 cm1.1651.059--1.283**0.002** Unknown0.9750.881--1.0800.635Number of tumors SingleReference Multiple1.0831.002--1.172**0.045**Distance metastasis NoReference Yes1.0910.816--1.4580.559 Unknown0.9080.639--1.2890.5876th AJCC TNM stage IReference II0.920.817--1.0370.174 III0.9010.824--0.986**0.025** IV0.940.700--1.2610.68 Unstaged1.0180.862--1.2030.836Pathological grade IReference II1.0380.899--1.1970.619 III1.0970.944--1.2760.226 IV0.9710.656--1.4380.886 Unstaged1.161.003--1.340**0.047**Abbreviation: *OR* odd ratio, *CI* confidence interval, *AFP* serum alpha fetoprotein, *AJCC* American Joint Committee on cancer

Balance between high- and low-Fb score groups {#Sec10}
---------------------------------------------

According to the propensity score model (Table [3](#Tab3){ref-type="table"}), PSM, excluding the prognosis indexes (vital status and survival time), achieved an adequate balance between the high- and low-Fb score groups. Notably, we found a decrease in SMDs between the two groups in the IPW analysis but not in PSM (Supplemental Table [1](#MOESM1){ref-type="media"} in Supplemental file [1](#MOESM1){ref-type="media"}). After PSM and IPW analyses, the variables between the two groups were significantly balanced because all the available *P* values were \> 0.05.

Overall survival analysis and competing risk survival analysis after matching {#Sec11}
-----------------------------------------------------------------------------

After matching, the KM curves (Fig. [3](#Fig3){ref-type="fig"}b and c) showed that a high-Fb score was a significant risk factor of OS in the matched cohort (HR 95%CI = 1.323 \[1.075--1.628\], *P* = 0.008). IPW analysis revealed similar results (HR 95%CI = 1.256 \[1.031--1.531\], *P* = 0.024). After PSM, the one-, three-, and five-year OS rates were 45.0, 26.0, and 10.2% in the low-Fb score group and 36.0, 8.1, and 2.3% in the high-Fb score group (*P* = 0.008), respectively. In the competing risk survival analysis, the propensity score-adjusted P values were 0.032 and 0.516 in the matching cohort after PS matching, (Fig. [4](#Fig4){ref-type="fig"}b).

Survival benefits of low-Fb scores in patients with surgical treatment {#Sec12}
----------------------------------------------------------------------

Figure [5](#Fig5){ref-type="fig"} shows the comparison results of the OS rates of patients who received surgery with different Fb scores after PSM. Compared with the patients in the low-Fb score group, those in the high-Fb score group had poorer OS rates, with the P values of the log-rank test between the two groups being 0.015 (Fig. [5](#Fig5){ref-type="fig"}a). In the comparison of the OS rates of patients without surgery records, different results were observed between the two groups (*P* = 0.466) (Fig. [5](#Fig5){ref-type="fig"}b). The subgroup survival analyses outcomes between the two groups of patients with and without the other two therapies are illustrated in Supplemental Figure [1](#MOESM2){ref-type="media"}. A subgroup analysis of the prognosis of ICC patients with different therapies was conducted. Supplemental Figure [2](#MOESM3){ref-type="media"} shows that in the surgery group, the patients' survival outcomes were not influenced by the treatment they received (i.e., chemotherapy and radiotherapy treatments) (*P* = 0.96 and 0.79). By contrast, chemotherapy and radiotherapy were significantly related to the prognosis of ICC patients in the none-surgery group (*P* \< 0.001). Fig. 5Overall survival in (**a**) the surgery recorded group and (**b**) the nonsurgery recorded group of matched cohort

Discussion {#Sec13}
==========

HCC is significantly correlated with liver fibrosis, and 80--90% of patients developed HCC with fibrotic or cirrhotic liver settings \[[@CR9]\]. However, due to the low incidence of ICC, few studies have focused on the role of liver fibrosis in the pathogenesis and mechanism of ICC. Recently, several researchers have found that CCAs usually occur in nonfibrotic livers but that they subsequently show a strong pro-connective tissue proliferation response similar to pancreatic cancer \[[@CR15]\]. Sirica AE et al. contended that CCA is characterized by a large number of desmoplastic reactions that do not depend on surrounding tissue fibrosis and can impact the values of Fb scores or other related indicators \[[@CR16]\]. The desmoplastic and hypovascularized nature of CCA is known to contribute to poor prognosis and therapy resistance \[[@CR10]\].

In our study, we found that a high-Fb score was significantly related to poor OS and DSS after PSM. The poor OS of patients with high-Fb scores was consistent after IPW analyses. Using the stratification analysis, we found that a high liver Fb score was significant in the poor prognostic outcomes of patients with records of common clinical treatments (surgery, radiation, and systemic chemotherapy). In addition, patients characterized as male and single and having AFP \> 15 ng/mL, tumor size ≤3 cm, multiple tumors, and stage III of the 6th AJCC stage were likely to have high-Fb scores.

At present, only a few studies have formally assessed the impact of Fb score on the prognosis of ICC patients after treatment. The current study is the first to explore the relationship between Fb score and ICC prognosis using the national SEER database. The results of our study demonstrated that relative to low-Fb scores, high-Fb scores impaired patients' survival outcomes, which were independent of the treatment methods. Moreover, ICC patients with low-Fb scores could obtain more survival benefits than those with high-Fb scores. Propensity scores were generated on the basis of a large number of factors that could affect treatment allocation, likely attenuating the possibility of allocation bias. We also attempted to control for an unmeasured confounder, that is, the presence of cirrhosis or advanced fibrosis, by using subgroup analyses.

Numerous researchers have reported the impact of fibrosis on HCC survival. In 2018, Sivesh K used the national SEER database and found that HCC patients with Fb scores of 0--4 had better survival rates than those with high-Fb scores after liver resection \[[@CR17]\]. Hui Liu et al. found that Fb score is an independent prognostic factor for OS but not for DSS \[[@CR18]\]. In 2014, Taiwan researchers found that severe liver fibrosis exerts a negative impact on OS and DSS in small HCC patients and that fibrosis is an independent predictor of tumor recurrence among patients who undergo hepatectomy \[[@CR19]\]. At present, no study has explored the relationship between the degree of liver fibrosis and prognosis in ICC. In our work, we included a large number of ICC patients regardless of the treatments they received. Our results are consistent with the aforementioned studies in HCC.

Researchers have found that CAFs are complex in terms of their contribution to the development and growth of CCA. Fibroblasts and the extracellular matrix (ECM) may play important tumor-promoting and tumor-restricting roles \[[@CR10]\]. Reports have shown that a high number of myofibroblasts or high expression of ECM proteins, such as periostin, is associated with a significantly low survival rate in CCA patients \[[@CR20]--[@CR22]\]. In the tumor microenvironment, CAFs produce and secrete a large amount of ECM proteins, and clinical evidence proves that stromal cells play an important role in tumor development. The aforementioned research might explain why patients with high-Fb scores are prone to having nonideal survival outcomes.

The mechanisms of how myofibroblasts and fibrosis affect the development and progression of CCA are intricate. Current evidence shows that CAFs promote the development and progression of CCA through a variety of mechanisms, which are likely to work together in complex multicellular signal networks. For example, a research found that tumor cells in ICC might produce a factor responsible for activating myofibroblasts and that the capacity of activation varies in each ICC patient \[[@CR21]\]. Claperon A et al. found that the cotransplantation of CCA tumor cells with human liver myofibroblasts increases tumor incidence, size, and metastatic dissemination in vivo; this effect can be inhibited by the EGFR tyrosine kinase inhibitor gefitinib \[[@CR23]\]. Moreover, coculture experiments demonstrate EGFR activation in tumor cells by myofibroblast-derived EGF, resulting in enhanced migratory and invasive properties in vitro \[[@CR23]\]. Fingas CD et al. found that myofibroblast-derived PDGF-BB promotes Hedgehog signaling-dependent survival signals in CCA cells \[[@CR24]\]. Aberrant Hedgehog signaling between stromal myofibroblastic cells and CCA cells is a critical modulator of intrahepatic CCA progression and therapy resistance. The main mechanism by which CAFs promote the progression of CCA is to support the proliferation and survival of tumor cells through the expression of cytokines and growth factors, such as periostin, thrombospondin-1, SDF-1, MMP2, MMP9, and IL-1β. Another mechanism is that cancer-associated fibroblasts modulate inflammation and immune responses in CCA \[[@CR10]\]. SDF-1 is the best characterized CAF-derived inflammatory mediator in CCA.

This study has several potential limitations. First, the SEER database lacks information on the fibrosis background of ICC patients. The SEER database also groups together patients with Fb scores of 0--4 and 5--6; hence, we could not perform our analysis according to different Fbs. Second, the pathological information of tumors in the SEER database is not openly available. Therefore, accurate TNM staging (the SEER database only contains the 6th AJCC stage) was not possible in this study. Third, the data on postoperative complications in the SEER database were limited, and a few patients received more than one treatment. These issues may affect the observation of the results of the impact of fibrosis on prognosis. Finally, SEER information comes from different registries. Hence, mistakes pertaining to the accuracy of the data are inevitable because no specialized staff is responsible for checking the data completely.

Conclusions {#Sec14}
===========

In liver, fibrosis is related to the survival outcome of ICC patients. It can be regarded as a predictor of prognosis for ICC patients who have received common therapies. Patients with low-Fb scores could benefit greatly from ICC treatments.
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 {#Sec15}

**Additional file 1:** **Additional file 2:Supplemental Figure 1.** Subgroup survival analyses for the prognosis of ICC patients with fibrosis scores. **Additional file 3:Supplemental Figure 2.** Subgroup analysis for the prognosis of ICC patients receiving different therapies.
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